The agreement is firmly geared towards the back end with an upfront fee of $30 million that gives Roche’s Genentech unit a buy-in to Bicycle’s bicyclic peptide drug discovery platform across a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback